Currently trading under six cents. Working with Becton Dickinson to develop test to detect early stage Alzheimers. Potential $500,000,000 annual market.
Company's patented MANF drug has several orphan indications.
Zachs' analyst Jason Napadano put a .20 price target on the stock and a buy rating on Monday.
Dr. Joesph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board. He reportebly said that AMBS is "the next Amgen in its infancy".
If China promotes their currency as a "gold backed" world standard currency to replace the dollar gold could double in a year.
Just a thought.
p.s. The miners are so undervalued I'm surprised that China hasn't pursued buying or investing in them.
"NUGT" - $150.00
NUGT is the best way to benefit from the rebound in the price of gold.
U.S. facing default and more money to flood the currency markets and gold is getting manipulated here.
Nothing has changed. The shareholders that believe in the company's eventual success won't be selling and may be adding shares if the share price drops tomorrow.
The current share price even with the additional dilution still undervalues the company by 70% or more.
The validation of LymPro by BD makes the dilution somewhat irrelevant in the long run.